23:20:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-02 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-26 Kvartalsrapport 2024-Q2
2024-05-15 Halvårsutdelning CONTX 0.15026
2024-05-14 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-02 Halvårsutdelning CONTX 0.15741
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-08 Halvårsutdelning CONTX 0.15741
2023-05-03 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning CONTX 0.00 NOK
2022-05-04 Årsstämma 2022
2022-04-21 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-12-10 Extra Bolagsstämma 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning CONTX 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Split CONTX 1:10
2020-08-13 Kvartalsrapport 2020-Q2
2020-08-05 Extra Bolagsstämma 2020
2020-05-07 Ordinarie utdelning CONTX 0.00 NOK
2020-05-06 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CONTX 0.00 NOK
2019-05-08 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-11 Ordinarie utdelning CONTX 0.00 NOK
2018-05-09 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-11 Ordinarie utdelning CONTX 0.00 NOK
2017-05-10 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-04-21 Kvartalsrapport 2016-Q1
2016-04-21 Ordinarie utdelning CONTX 0.00 NOK
2016-04-20 Årsstämma 2016
2016-02-18 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-04-23 Ordinarie utdelning CONTX 0.00 NOK
2015-04-23 Kvartalsrapport 2015-Q1
2015-04-22 Årsstämma 2015
2015-02-19 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-12 15-7 2014
2014-04-24 Ordinarie utdelning CONTX 0.00 NOK
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-23 Årsstämma 2014
2014-02-20 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-06-13 Ordinarie utdelning CONTX 0.00 NOK
2013-06-12 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-21 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-06-14 Ordinarie utdelning CONTX 0.00 NOK
2012-06-13 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-23 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-06-10 Ordinarie utdelning CONTX 0.00 NOK
2011-06-09 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-17 Bokslutskommuniké 2010
2010-10-21 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-04 Ordinarie utdelning CONTX 0.00 NOK
2010-06-03 Årsstämma 2010
2010-04-21 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-23 Kvartalsrapport 2009-Q1
2008-06-06 Ordinarie utdelning CONTX 1.50 NOK

Beskrivning

LandSverige
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
ContextVision är ett medicinteknologiskt bolag. Bolaget specialiserar sig inom bildanalys och artificiell intelligens. Bland bolagets produkter återfinns avancerade bildförbättringsprogram för ultraljud, MRI, röntgen och mammografi. Programvarorna används idag av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1983 och har sitt huvudkontor i Stockholm.
2021-11-15 12:25:22

STOCKHOLM – Nov 15, 2021 - ContextVision, a medical technology software company specializing in image processing and decision support tools within digital pathology, today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.

The updated strategy means that the company will continue to develop its machine learning technology for its own laboratory service, and let go of the present business strategy of developing and selling decision support tools for existing laboratories.

We are convinced about this strategic turn. It is a huge opportunity to create a paradigm shift by making use of the investments we have made in AI-technology and application knowledge. It will accelerate further development with the aim to improve patient care, while creating sustainable shareholder value.” says CEO Fredrik Palm of ContextVision.

The rationale behind the decision
As recently announced, clinical evaluations with pathology labs in Europe and the United States show that the company’s first product, INIFY Prostate, seems to be one of the most accurate and advanced decision support tools in the world today.

Despite that, reality shows that the transformation from analogue to digital workflow in existing clinical pathology laboratories around the world is highly complex, from a both technical, legacy, and commercial perspective. The current level of fully digitalized labs remains very low, and extensive investigations have not been able to foresee when digital decision support tools reach a stage where they become routine and standard of care, and thereby becoming a sustainable business.

However, the enormous value of a fully digitalized lab, with standardized processes and a common data model, makes the business case for an AI based pathology lab service clear. Here, INIFY will be the core machine learning technology that will be a cornerstone for the new laboratory service.

Laboratory scope
Expanding the company’s scope by building a fully digital laboratory enables faster implementation of technology and workflow improvements, thus creating maximum value for patients, clinicians and pathologists.

One of the success factors is our establishment of a cross-functional team with clinical and technical expertise, arranged in the same organization with a common goal – to improve patient care and healthcare service. Recruitment has started, and our international network of highly respectable medical professionals and partners will have the opportunity to be a part of our organization as it is built up,” says Palm.

Standardized data allows for seamless, continuous development of powerful machine learning technology and process optimization within the laboratory. This in turn will provide both employed and consultant pathologists with valuable tools and prerequisites, maximizing diagnosis efficiency and quality.

To be honest, my greatest challenge before we started this strategic project was to figure out how to transform our investments in powerful technology and valuable know-how into a sustainable, growing business. We not only found a solid solution, but also created a comprehensive strategy for our path forward,” Palm summarizes.

###

For further information, please contact ContextVision's CEO, Fredrik Palm, fredrik.palm@contextvision.se or visit www.contextvision.com

###

About ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X- ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools, and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
This information is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation.